Study of serum uric acid level in chronic liver disease and its association with hepatic encephalopathy and LFT parameters
DOI:
https://doi.org/10.18203/2320-6012.ijrms20244120Keywords:
Chronic liver disease, Serum uric acid, Hepatic encephalopathy, Liver cirrhosis, Liver function testsAbstract
Background: Chronic liver disease (CLD) is a progressive condition associated with complications such as hepatic encephalopathy (HE), a neuropsychiatric manifestation linked to altered purine metabolism and serum uric acid (SUA) levels. While liver function tests (LFTs) evaluate liver health, the role of SUA in CLD, particularly its correlation with HE severity and LFT parameters, remains underexplored. To investigate serum uric acid levels in CLD patients and examine their correlation with HE severity and LFT parameters.
Methods: This cross-sectional study included 54 CLD patients aged 18-85 years from GSVM Medical college Kanpur, selected via random sampling. Clinical and biochemical data, including SUA levels and LFTs, were collected and analysed. Statistical analyses using ANOVA and Pearson correlation assessed associations between SUA, HE grades, and LFT parameters.
Results: Serum uric acid levels significantly correlated with HE severity (ANOVA: F=6.93, p<0.05), with mean SUA levels rising from 6.28 mg/dL in Grade 0 to 10.41 mg/dl in Grade 2 HE. SUA demonstrated significant negative correlation with serum albumin (r = -0.36, p<0.05) and positive correlations with PT-INR (r = 0.33, p<0.05) and creatinine (r = 0.55, p<0.05). No significant correlation was observed with bilirubin, SGOT or SGPT.
Conclusions: Elevated SUA levels are significantly associated with the severity of hepatic encephalopathy and key LFT parameters. SUA may serve as a valuable biomarker for assessing CLD progression and predicting complications like HE.
Metrics
References
García-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension". Hepatology. 2009:49(2):471-85.
Memon FA, Butt SA, Shaikh MK, Memon SA, Bhutto IA, Jat AHM. Hyperuricemia in Patients with Chronic Liver Disease. In: Medical Forum Monthly. 2021;32.
Benerji D. Comparative Study of ALT, AST, GGT & Uric Acid Levels in Liver Diseases. IOSR J Dent Med Sci. 2013;7:72-5.
Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Practice & Research Clinical Gastroenterology. 2007;21(1):95-110.
Bernardi, M. Hyperuricemia and oxidative stress in liver disease: Pathophysiological links and clinical implications. Hepatology International. 2019;13(3):297-308.
Jiang H. Serum uric acid as a biomarker for hepatic and renal function in chronic liver disease patients. European Journal of Gastroenterology & Hepatology, 2015;27(7):782-9.
Hasan R, Roy PK, Khan MR. Relation Of Serum Uric Acid Concentrations With Etiology And Severity In Patients With Cirrhosis Of Liver. Auctores Publishing LLC, ed. Gastroenterol Pancreatol Hepatobilary Disord. 2021;5(2):1-6.
Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatol Baltim Md. 2010;52(2):578-89.
Wang Q. Serum uric acid levels and their association with liver function and disease severity in chronic liver disease patients. Journal of Hepatology. 2016;64(5):1031-8.
Frelikh M. The role of serum uric acid in predicting outcomes of hepatic encephalopathy in cirrhotic patients. Liver International. 2019;39(2):271–9.
Shastry S. Hyperuricemia as a predictor of hepatic and renal impairment in advanced liver disease". World Journal of Gastroenterology. 2020;26(17):1960–71.
Khan M. The prognostic role of serum uric acid in liver disease progression and complications. World Journal of Hepatology. 2021;13(4):520-31.
Friedman LS. Liver function tests and the diagnosis of liver disease. Clinical Cornerstone. 2003;5(3):1-12.
Downloads
Published
How to Cite
Issue
Section
